About 13 results found for searched term "FX1" (0.054 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M4847 | Tafamidis | Transthyretin (TTR) |
| Fx-1006A, Vyndaqel | ||
| Tafamidis is a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade, with EC50s of 2.7-3.2 μM to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR. | ||
| M6207 | FX1 | Others |
| FX1 is a potent and specific BCL6 inhibitor, with an IC50 of around 35 μM. | ||
| M14457 | FX-11 | LDH |
| LDHA Inhibitor FX11 | ||
| FX-11 (LDHA Inhibitor FX11) is a potent lactate dehydrogenase A (LDHA) inhibitor with an IC50 of 23.3 μM for HeLa cell and a Ki value of 8 μM. FX-11 can reduce ATP levels, induce oxidative stress and ROS production, and cause cell death. | ||
| M14778 | Tafamidis meglumine | Transthyretin (TTR) |
| Fx-1006A | ||
| Tafamidis meglumine (Fx-1006A) is a potent and selective transthyretin (TTR) stabilizer, shows comparable potency and efficacy to the mutumant homotetramers V30M-TTR, V122I-TTR and wild type WT-TTR, with EC50s of 2.7-3.2 μM. | ||
| M25043 | Vilobelimab | Complement System |
| CaCP-29, IFX-1 | ||
| Vilobelimab (CaCP-29, IFX-1) is a monoclonal anti-C5a antibody to the allergen C5a, a pro-inflammatory complement division product that plays a central role in mediating organ dysfunction. Vilobelimab acts as a C5a inhibitor, inhibiting neutrophil activation, chemotaxis, and reducing inflammatory signalling, and may be used in studies related to sepsis, COVID-19, etc. | ||
| M27725 | Temafloxacin hydrochloride | Antibiotic |
| TMFX hydrochloride; TA-167; A-62254 | ||
| Temafloxacin (TMFX) hydrochloride is an orally active quinolone broad-spectrum antibacterial agent. Temafloxacin hydrochloride is well tolerated in lower respiratory and genitourinary tract infections. | ||
| M27765 | Temafloxacin | Antibiotic |
| TMFX; TA-167 free acid; A-62254 free acid | ||
| Temafloxacin (TMFX) is an orally active quinolone broad-spectrum antibacterial agent. Temafloxacin is well tolerated in lower respiratory and genitourinary tract infections. | ||
| M28886 | FXIa-IN-1 | Factor Xa |
| FXIa-IN-1 (compound EP-7041) is a potent β-lactam covalent heparin-derived factor XIa (fXIa) inhibitor. | ||
| M40978 | FXR-314 | Farnesoid X Receptor |
| FXR-314 is an FXR agonist that can be used in studies related to non-alcoholic steatohepatitis (NASH). | ||
| M42398 | FXIa-IN-13 | Factor Xa |
| FXIa-IN-13 is an Factor Xa inhibitor with antithrombotic activity. | ||
| M43100 | FXIIa-IN-1 | Others |
| XIIa-IN-1-IN-3 is a Factor XIIa inhibitor (Kiapp: 97.8 nM). | ||
| M45253 | AFX-2101 | HMGB1 |
| AFX-2101 is a high mobility group protein B1 (HMGB1) modulator for studies related to CNS trauma. | ||
| M57957 | CPFX4158 | Others |
| CPFX4158 | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
